Agile therapeutics reports first quarter 2020 financial results

Agile therapeutics reports first quarter 2020 financial results.q1 loss per share $0.10.q1 earnings per share estimate $-0.09 -- refinitiv ibes data.93.9 million in cash and cash equivalents as of march 31, 2020.expects operating expenses for full year 2020 to be in range of $52.0 million to $56.0 million.net revenue in q4 of 2020, reflecting initial launch of twirla, is expected to be in range of $4.0 million to $6.0 million.
AGRX Ratings Summary
AGRX Quant Ranking